Graph Therapeutics brings total funding to over $10M to advance precision immunology
Graph Therapeutics, a next-generation techbio company developing precision medicinesfor inflammatory and immune-mediated diseases, has secured a new $5 millioninvestment led by Daphni, the Paris-based... Graph Therapeutics is a biotech company developing precision medicines for inflammatory and immune-mediated diseases using AI-powered analysis of live patient cells, multi-omics data, and functional biology.
Key Takeaways
- Biotech Graph Therapeutics brings total funding to over $10M to advance precision immunology Graph Therapeutics is a biotech company developing precision medicines for inflammatory and immune-mediated diseases using AI-powered analysis of live patient cells, multi-omics data, and functional biology.
Daphni joins Graph's existing investor syndicate, which includes SquareOne, Merantix Capital, and NAVEC Investment Management.
- With this latest financing, Graph has raised more than $10 million to date, including equity investments and non-dilutive grant funding.
Graph combines perturbation modelling of complex live patient samples, functional and multi-omics profiling, and advanced machine learning through its proprietary "lab-in-the-loop" AI platform to decode immune dysfunction at scale.
- Building on a platform that has been substantially validated and de-risked, Graph is advancing an internal pipeline of precision therapeutics targeting complex inflammatory and immune-mediated diseases.
The company has significantly de-risked and validated its platform through clinically relevant biological models, creating a strong foundation for the development of novel therapeutic programs.
- The new capital will support the advancement of Graph's internal drug discovery pipeline across multiple inflammatory and immune-mediated disease indications, while further expanding the company's platform capabilities and strategic partnership opportunities.
Graph Therapeutics Write Comment Graph Therapeutics brings total funding to over $10M to advance precision immunology Comments Would you like to write the first comment?
- What would you like us to deliver to you?
Stats & Key Facts
- #Graph Therapeutics, a next-generation techbio company developing precision medicinesfor inflammatory and immune-mediated diseases, has secured a new $5 millioninvestment led by Daphni, the Paris-based...
- #Biotech Graph Therapeutics brings total funding to over $10M to advance precision immunology Graph Therapeutics is a biotech company developing precision medicines for inflammatory and immune-mediated diseases using AI-powered analysis of live patient cells, multi-omics data, and functional biology.
- #Tamara Djurickovic 1 hour ago Share Share Send email Copy link Graph Therapeutics , a next-generation techbio company developing precision medicines for inflammatory and immune-mediated diseases, has secured a new $5 million investment led by Daphni , the Paris-based venture capital firm.
- #With this latest financing, Graph has raised more than $10 million to date, including equity investments and non-dilutive grant funding.
Graph Therapeutics is a biotech company developing precision medicines for inflammatory and immune-mediated diseases using AI-powered analysis of live patient cells, multi-omics data, and functional biology. Biotech Graph Therapeutics brings total funding to over $10M to advance precision immunology Graph Therapeutics is a biotech company developing precision medicines for inflammatory and immune-mediated diseases using AI-powered analysis of live patient cells, multi-omics data, and functional biology. Tamara Djurickovic 1 hour ago Share Share Send email Copy link Graph Therapeutics , a next-generation techbio company developing precision medicines for inflammatory and immune-mediated diseases, has secured a new $5 million investment led by Daphni , the Paris-based venture capital firm.
Daphni joins Graph's existing investor syndicate, which includes SquareOne, Merantix Capital, and NAVEC Investment Management. The company has also secured additional non-dilutive funding from the Austrian Research Promotion Agency (FFG) and Austria Wirtschaftsservice (AWS). With this latest financing, Graph has raised more than $10 million to date, including equity investments and non-dilutive grant funding.
Graph combines perturbation modelling of complex live patient samples, functional and multi-omics profiling, and advanced machine learning through its proprietary "lab-in-the-loop" AI platform to decode immune dysfunction at scale. By generating insights directly from real patient tissue, the company identifies disease mechanisms, novel therapeutic targets, and biomarkers that inform the development of differentiated therapies. Building on a platform that has been substantially validated and de-risked, Graph is advancing an internal pipeline of precision therapeutics targeting complex inflammatory and immune-mediated diseases.
For more details please read the original article at Tech.eu.
Continue Learning
Comments
Sign in to join the conversation